🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06203249
Recruiting Observational

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

NCT06203249 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2024-01-20
Last updated
2024-01-12

Condition(s) studied

MicrobiomeImmune FunctionAnti-MDA5 Antibody Positive Dermatomyositis

Study summary

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive. * Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD. * Must have undergone bronchoalveolar lavage. * Age≥18 years old. * Patients who signed informed consent forms Exclusion Criteria: * Patients who had other connective tissue diseases. * Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors. * Pregnant or lactating patients. * The patient also participated in any other clinical trial. * Disagreement for inclusion in this study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
PLA Beijing Beijing Municipality Recruiting

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06203249 on ClinicalTrials.gov ↗ ← All trials in China